Brianna Hoffner

2.0k total citations
21 papers, 291 citations indexed

About

Brianna Hoffner is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Brianna Hoffner has authored 21 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Brianna Hoffner's work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Melanoma and MAPK Pathways (4 papers). Brianna Hoffner is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Melanoma and MAPK Pathways (4 papers). Brianna Hoffner collaborates with scholars based in United States, Italy and Germany. Brianna Hoffner's co-authors include Omid Hamid, Eduard Gasal, Richard D. Carvajal, Jenny J. Hong, Marianne Davies, Natasha B. Leighl, Krista M. Rubin, Víctor M. Villalobos, Anthony Elias and Susan Bauer‐Wu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Brianna Hoffner

19 papers receiving 287 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brianna Hoffner United States 9 153 99 56 55 54 21 291
Jacalyn B. Gano United States 9 152 1.0× 126 1.3× 65 1.2× 114 2.1× 56 1.0× 15 390
Vanessa Wong Australia 8 95 0.6× 31 0.3× 64 1.1× 74 1.3× 25 0.5× 38 301
S. Srinivas United States 8 125 0.8× 94 0.9× 81 1.4× 50 0.9× 15 0.3× 33 290
Mark R. Openshaw United Kingdom 11 92 0.6× 90 0.9× 21 0.4× 46 0.8× 16 0.3× 27 350
Christine Merenda United States 9 116 0.8× 126 1.3× 36 0.6× 50 0.9× 57 1.1× 17 399
Aine Clements United States 13 136 0.9× 90 0.9× 52 0.9× 37 0.7× 13 0.2× 27 422
Yanli Xu China 12 65 0.4× 83 0.8× 34 0.6× 43 0.8× 45 0.8× 38 325
Karishma Mehra United States 10 93 0.6× 134 1.4× 54 1.0× 53 1.0× 42 0.8× 11 578
Minako Iida Japan 7 102 0.7× 80 0.8× 18 0.3× 23 0.4× 105 1.9× 13 436
Anna Tomiak Canada 8 148 1.0× 97 1.0× 67 1.2× 54 1.0× 11 0.2× 11 331

Countries citing papers authored by Brianna Hoffner

Since Specialization
Citations

This map shows the geographic impact of Brianna Hoffner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brianna Hoffner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brianna Hoffner more than expected).

Fields of papers citing papers by Brianna Hoffner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brianna Hoffner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brianna Hoffner. The network helps show where Brianna Hoffner may publish in the future.

Co-authorship network of co-authors of Brianna Hoffner

This figure shows the co-authorship network connecting the top 25 collaborators of Brianna Hoffner. A scholar is included among the top collaborators of Brianna Hoffner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brianna Hoffner. Brianna Hoffner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marron, Thomas U., Jason J. Luke, Brianna Hoffner, et al.. (2025). A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 13(3). e010760–e010760. 1 indexed citations
2.
Hochhaus, Andreas, Susanne Saußele, Valérie Coiteux, et al.. (2025). Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts. Blood. 146(Supplement 1). 3771–3771.
3.
Hoffner, Brianna, et al.. (2023). What Does Dobbs v. Jackson Mean for Oncology Patients and Providers? Current Considerations for Pregnancy and Fertility in the Oncology Setting. Journal of the Advanced Practitioner in Oncology. 14(3). 191–194. 2 indexed citations
4.
Boehmer, Leigh, Brianna Hoffner, Yurii B. Shvetsov, et al.. (2022). Role of Oncology Advanced Practitioners to Enhance Clinical Research. Journal of the Advanced Practitioner in Oncology. 13(2). 107–119. 11 indexed citations
5.
Hoffner, Brianna, Natasha B. Leighl, & Marianne Davies. (2020). Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer Treatment Reviews. 85. 101979–101979. 24 indexed citations
6.
Boehmer, Leigh, Brianna Hoffner, Jessica Rhee, et al.. (2020). Role of oncology-advanced practitioners to enhance clinical research.. Journal of Clinical Oncology. 38(29_suppl). 95–95.
7.
Rubin, Krista M., et al.. (2019). Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. Seminars in Oncology Nursing. 35(5). 150924–150924. 1 indexed citations
8.
Hoffner, Brianna & Krista M. Rubin. (2019). Meeting the Challenge of Immune-Related Adverse Events With Optimized Telephone Triage and Dedicated Oncology Acute Care. Journal of the Advanced Practitioner in Oncology. 10(2). 9–20. 13 indexed citations
9.
Wood, Laura S., Brianna Hoffner, Krista M. Rubin, et al.. (2019). Managing immune-related adverse events (irAEs): A new educational resource for health care professionals (HCPs) and patients.. Journal of Clinical Oncology. 37(8_suppl). 75–75. 2 indexed citations
10.
Hoffner, Brianna, Anthony Elias, & Víctor M. Villalobos. (2018). Targeted Therapies in the Treatment of Sarcomas. Targeted Oncology. 13(5). 557–565. 6 indexed citations
11.
Hoffner, Brianna, et al.. (2018). Trametinib: A Targeted Therapy in Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology. 9(7). 741–745. 37 indexed citations
12.
Hamid, Omid, Brianna Hoffner, Eduard Gasal, Jenny J. Hong, & Richard D. Carvajal. (2017). Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunology Immunotherapy. 66(10). 1249–1264. 60 indexed citations
13.
Villalobos, Víctor M., F. De Havilland Hall, Antonio Jimeno, et al.. (2017). Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Annals of Surgical Oncology. 25(3). 768–775. 48 indexed citations
14.
15.
Hoffner, Brianna & Daniel M. Siegel. (2017). Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma. Journal of the Advanced Practitioner in Oncology. 8(3). 244–248. 1 indexed citations
16.
Hoffner, Brianna, et al.. (2016). Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. Oncology nursing forum. 43(2). 219–226. 15 indexed citations
17.
Olszanski, Anthony J. & Brianna Hoffner. (2016). Evolving Paradigms in Melanoma Therapy. Journal of the Advanced Practitioner in Oncology. 7(3). 291–294. 1 indexed citations
18.
Flaherty, Devin C., Brianna Hoffner, Briana J. Lau, Omid Hamid, & Mark B. Faries. (2015). Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma. Journal of Surgical Oncology. 112(8). 844–845. 5 indexed citations
19.
Trivedi, Meghna S., et al.. (2015). Programmed death 1 immune checkpoint inhibitors.. PubMed. 13(12). 858–68. 23 indexed citations
20.
Hoffner, Brianna, et al.. (2011). “Entering a clinical trial: Is it right for you?”. Cancer. 118(7). 1877–1883. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacalyn B. Gano Breakdown of academic impact, for papers by Vanessa Wong Breakdown of academic impact, for papers by S. Srinivas Breakdown of academic impact, for papers by Mark R. Openshaw Breakdown of academic impact, for papers by Christine Merenda Breakdown of academic impact, for papers by Aine Clements Breakdown of academic impact, for papers by Yanli Xu Breakdown of academic impact, for papers by Karishma Mehra Breakdown of academic impact, for papers by Minako Iida Breakdown of academic impact, for papers by Anna Tomiak
Rankless by CCL
2026